When to Order Imaging for Hematospermia: ACR Appropriateness Decoded
When to Order Imaging for Hematospermia: ACR Appropriateness Decoded
A 32-year-old male presents to your clinic with a single episode of blood in his semen, discovered yesterday. He is anxious but otherwise has no urinary symptoms, pain, or history of trauma. Your differential includes benign, self-limiting causes, but the possibility of something more serious lingers. Do you order imaging? If so, which study? The American College of Radiology (ACR) provides evidence-based guidelines to navigate this common but often alarming presentation. This article decodes the ACR Appropriateness Criteria for hematospermia, helping you choose the right imaging path for your patient.
What Does the ACR Guidance on Hematospermia Cover?
The ACR Appropriateness Criteria for hematospermia focus on the initial imaging workup for male patients presenting with blood in their ejaculate. The guidance is stratified into two primary clinical scenarios based on risk factors that correlate with the likelihood of significant underlying pathology, such as malignancy. The key differentiating factors are age, the persistence or recurrence of symptoms, and the presence of associated signs like hematuria or a palpable abnormality.
This document specifically addresses initial diagnostic imaging. It does not cover imaging for patients with a known diagnosis (e.g., prostate cancer surveillance), post-procedural hematospermia (such as after a prostate biopsy), or presentations primarily defined by other symptoms like gross hematuria, for which separate ACR guidelines exist. The core purpose is to guide clinicians in distinguishing between low-risk patients who rarely require imaging and higher-risk patients for whom a targeted workup is warranted.
What Imaging Should I Order for Hematospermia? Recommendations by Clinical Scenario
The ACR’s recommendations hinge on a critical risk stratification. The approach for a young patient with a transient episode is vastly different from that for an older patient or one with persistent symptoms.
For a male less than 40 years of age with transient hematospermia and no associated signs or symptoms of disease, the ACR guidance is clear: initial imaging is Usually not appropriate. This recommendation applies across all modalities, including Transrectal Ultrasound (TRUS), scrotal ultrasound, MRI, and CT. The rationale is that in this younger, asymptomatic population, hematospermia is overwhelmingly benign and self-limiting, often attributed to inflammation or infection of the prostate or seminal vesicles. The potential harms of imaging, including cost, radiation exposure from CT, and patient anxiety, are not justified by the extremely low diagnostic yield for clinically significant findings.
The imaging strategy changes significantly for a male aged 40 or older, or a male of any age with persistent or recurrent hematospermia, or hematospermia accompanied by associated signs or symptoms of disease. In this higher-risk cohort, imaging is warranted to evaluate for underlying structural abnormalities or malignancy. The ACR rates MRI of the pelvis without and with IV contrast as Usually appropriate. This study provides excellent soft-tissue resolution to assess the prostate, seminal vesicles, and adjacent structures without using ionizing radiation. For a detailed look at the technique, see our guide on MRI Prostate (Multiparametric).
Several other studies are rated as May be appropriate in this higher-risk group. TRUS of the prostate can be useful for evaluating the prostate and seminal vesicles and can guide a biopsy if needed, though its field of view is more limited than MRI. A scrotal ultrasound may be considered if there are associated scrotal symptoms or a palpable testicular or epididymal abnormality. If there is a contraindication to IV contrast, an MRI of the pelvis without IV contrast is also rated as May be appropriate. Various CT protocols, such as CT Abdomen/Pelvis Without Contrast (Renal Stone), may also be appropriate, particularly if there is suspicion of urolithiasis or a need to evaluate the entire urinary tract.
ACR Imaging Recommendations Table for Hematospermia
| Clinical Scenario | Top Procedure | ACR Rating | Adult RRL | Pediatric RRL |
|---|---|---|---|---|
| Male. Less than 40 years of age. Transient hematospermia. No associated signs or symptoms of disease. Initial imaging. | TRUS prostate | Usually not appropriate | O 0 mSv | O 0 mSv [ped] |
| Male. Greater than or equal to 40 years of age with hematospermia; or male of any age with persistent or recurrent hematospermia or hematospermia accompanied by associated signs or symptoms of disease. Initial imaging. | MRI pelvis without and with IV contrast | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
Adult vs. Pediatric Hematospermia Imaging: Radiation Dose Tradeoffs
Hematospermia is uncommon in the pediatric population but can occur, often causing significant parental concern. While the ACR variants provided do not create a separate pediatric-only scenario, the principles of risk stratification and radiation safety are paramount. For the low-risk presentation (transient, asymptomatic), the “Usually not appropriate” rating for all imaging studies inherently protects younger patients from unnecessary radiation exposure, aligning perfectly with the As Low As Reasonably Achievable (ALARA) principle.
In the rare case a pediatric or adolescent patient falls into the higher-risk category (persistent or symptomatic), the choice of imaging modality must carefully weigh diagnostic need against cumulative radiation dose. The ACR ratings favor non-ionizing studies like MRI (0 mSv) as “Usually appropriate.” When CT is considered, it’s critical to note the relative radiation level (RRL) symbols. For example, a CT of the abdomen and pelvis with IV contrast carries an RRL of ☢ ☢ ☢ (1-10 mSv) for adults but ☢ ☢ ☢ ☢ (3-10 mSv [ped]) for pediatric patients. This higher pediatric rating for a similar dose range reflects the increased lifetime cancer risk from radiation exposure at a younger age. Therefore, MRI is the strongly preferred modality for advanced pelvic imaging in younger patients when indicated.
Imaging Protocol Details for Hematospermia
Once you’ve decided on the right study based on the clinical scenario, ensuring it is performed correctly is the next critical step. The specific imaging protocol—including MRI sequences, contrast timing, and CT parameters—directly impacts diagnostic quality. Our protocol guides provide detailed, scannable information for the key studies recommended in these guidelines.
Tools to Help You Order the Right Study
Navigating imaging guidelines can be complex, especially when managing multiple clinical presentations. GigHz offers a suite of reference tools designed to support evidence-based ordering and enhance communication with patients and radiologists.
For clinical questions beyond hematospermia, the ACR Appropriateness Criteria Lookup provides a searchable interface to find the official ACR guidance for thousands of clinical variants. It helps ensure you are always aligning your orders with the latest expert panel recommendations.
To access detailed technical specifications for hundreds of imaging studies, including the MRI and CT scans discussed here, the Imaging Protocol Library is an essential resource. It provides standardized, easy-to-read protocols to help you understand what you are ordering and what to expect from the results.
When discussing studies that involve ionizing radiation, the Radiation Dose Calculator is an invaluable tool. It helps you estimate effective radiation dose for various exams, track cumulative exposure for your patients, and communicate radiation risk in clear, understandable terms.
Frequently Asked Questions about Imaging for Hematospermia
Why is age 40 the primary cutoff for imaging in hematospermia?
The age of 40 is used as a risk stratification threshold because the incidence of significant underlying pathology, particularly prostate and urogenital malignancies, begins to increase around this age. In men under 40, hematospermia is almost always caused by benign, self-limiting conditions like infection or inflammation. In men 40 and older, while benign causes are still most common, the pre-test probability of a serious condition is high enough to justify an imaging workup.
Is a digital rectal exam (DRE) still necessary before ordering imaging?
Yes, a thorough history and physical examination, including a digital rectal exam (DRE), are essential parts of the initial workup for hematospermia, especially in the higher-risk group (age ≥40 or persistent/symptomatic). A DRE can detect prostate abnormalities such as nodules, asymmetry, or induration that may warrant further investigation with imaging and/or a Prostate-Specific Antigen (PSA) test. The clinical findings help guide the choice and urgency of imaging.
When should I choose Transrectal Ultrasound (TRUS) over MRI?
For a comprehensive diagnostic evaluation of the prostate and seminal vesicles, MRI is generally the preferred modality due to its superior soft-tissue contrast and larger field of view. The ACR rates MRI as “Usually appropriate” in the higher-risk group. TRUS, rated as “May be appropriate,” is most valuable when a prostate biopsy is being considered, as it provides real-time guidance for needle placement. It can also be a reasonable alternative if MRI is unavailable or contraindicated.
What if my patient has a contraindication to MRI contrast?
If a patient has a severe allergy to gadolinium-based contrast agents or has severe renal insufficiency (low eGFR), a non-contrast study should be performed. The ACR rates MRI of the pelvis without IV contrast as “May be appropriate” for higher-risk patients. While contrast enhances the detection of inflammation and some tumors, a non-contrast MRI can still provide excellent anatomical detail of the prostate, seminal vesicles, and bladder, often sufficient to identify significant structural causes of hematospermia.
Does a negative imaging study rule out all serious causes of hematospermia?
A negative imaging study, such as a normal pelvic MRI, significantly lowers the likelihood of a structural or malignant cause (e.g., tumor, large cyst, or abscess). However, it does not entirely rule out all serious pathology. Microscopic or diffuse inflammatory or infectious conditions may not have distinct imaging findings. Therefore, clinical judgment and follow-up are crucial. If hematospermia persists despite a negative workup, further urologic evaluation is warranted.
Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026
